Abstract:Background & Aims Persons with chronic hepatitis B virus (HBV) infection coinfected with HIV experience accelerated progression of liver fibrosis compared to those with HBV mono-infection. We hypothesize that HIV and its proteins promote HBV-induced liver fibrosis in HIV/HBV coinfected cell culture models through HIF-1α and TGF-β1 signaling. Methods The HBV positive supernatant, purified HBV viral particles, HIV positive supernatant, or HIV viral particles were directly incubated (or infected) with cell lines or primary cells of hepatocytes, hepatic stellate cells, and macrophages in mono or 3D spheroid coculture models. Cells were incubated with recombinant cytokines and HIV proteins including gp120. HBV subgenomic constructs were transfected into NTCP-HepG2 cells. We also evaluated the effects of inhibitors of HIF-1α and HIV gp120 in a HBV carrier mouse model that was generated by hydrodynamic injection of pAAV/HBV1.2 plasmid through the tail vein of wild-type C57BL/6 mice. Results We found that HIV and HIV gp120, through engagement with CCR5 and CXCR4 coreceptors, activate AKT and ERK signaling and subsequently upregulate hypoxia-inducible factor-1α (HIF-1α) to increase HBV-induced transforming growth factor beta 1 (TGF-β1) and profibrogenic gene expression in hepatocytes and hepatic stellate cells (HSC). HIV gp120 exacerbates HBV X protein-mediated HIF1α expression and liver fibrogenesis, which can be alleviated by inhibiting HIF-1α. Conversely, TGF-β1 upregulates HIF-1α expression and HBV-induced liver fibrogenesis through the SMAD signaling pathway. HIF-1α siRNA transfection or the HIF-1α inhibitor (Acriflavine) blocked HIV, HBV, and the TGF-β1-induced fibrogenic response. Conclusions Our findings suggest that HIV coinfection exacerbates HBV-induced liver fibrogenesis through enhancement of the positive feedback between HIF-1α and TGF-β1 through CCR5/CXCR4. HIF-1α represents a novel target for antifibrotic therapeutic development in HBV/HIV coinfection. Impact and implications HIV coinfection accelerates the progression of liver fibrosis compared to HBV mono-infection, even among patients with successful suppression of viral load, and there is no sufficient treatment for this disease process. In this study, we found that HIV viral particles and specifically HIV gp120 promote HBV-induced hepatic fibrogenesis via enhancement of the positive feedback between HIF-1α and TGF-β1, which can be ameliorated by inhibition of HIF-1α. These findings suggest that targeting the HIF-1α pathway can reduce the liver fibrogenesis of patients with HIV and HBV coinfection.

HIV/HBV coinfection: understanding the complex interactions and their impact on spontaneous HBV clearance, chronic liver damage, cirrhosis, and hepatocellular carcinoma

HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Hepatitis B and human immunodeficiency virus coinfection

Cytokines and Chemokines in HBV Infection

HIV-HBV Coinfection—Current Challenges for Virologic Monitoring

Hepatitis B in the HIV-coinfected patient

Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis.

Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment

Microbiota-Meditated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review

HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection

Human Cytomegalovirus and Epstein-Barr Virus Infections, Risk Factors, and Their Influence on the Liver Function of Patients with Acute-on-chronic Liver Failure

Increased HBV Coinfection and Decreased IFN-γ-Producing HBV-Specific CD8+ T Cell Numbers During HIV Disease Progression

HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway

HBV Rewires Liver Cancer Signaling by Altering PP2A Complexes

Hepatitis B viral replication markers and hepatic fibrosis in untreated chronic hepatitis B virus infection with and without HIV coinfection in Zambia

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection

Suggestion on treatment for HIV/HBV,HIV/HCV coinfection

Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicentre Descriptive Study

Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk

Host and HBV Interactions and Their Potential Impact on Clinical Outcomes